A New Mouse Model of APOL1-Associated Kidney Diseases: When Traffic Gets Snarled, the Podocyte Suffers.

[1]  A. Quyyumi,et al.  A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease , 2017, Nature Medicine.

[2]  J. Das,et al.  APOL1-G1 in Nephrocytes Induces Hypertrophy and Accelerates Cell Death. , 2017, Journal of the American Society of Nephrology : JASN.

[3]  M. Schuldiner,et al.  APOL1-Mediated Cell Injury Involves Disruption of Conserved Trafficking Processes. , 2017, Journal of the American Society of Nephrology : JASN.

[4]  T. Manolio,et al.  Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans. , 2017, Journal of the American College of Cardiology.

[5]  Rennie Negron,et al.  Race, Genomics and Chronic Disease: What Patients with African Ancestry Have to Say , 2017, Journal of health care for the poor and underserved.

[6]  Patrick D. Dummer,et al.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice , 2017, Nature Medicine.

[7]  R. Cooper,et al.  APOL1, α-thalassemia, and BCL11A variants as a genetic risk profile for progression of chronic kidney disease in sickle cell anemia , 2017, Haematologica.

[8]  C. Nast,et al.  Collapsing glomerulopathy in a young woman with APOL1 risk alleles following acute parvovirus B19 infection: a case report investigation , 2016, BMC Nephrology.

[9]  Victor G. Puelles,et al.  APOL1 Risk Alleles Are Associated With More Severe Arteriosclerosis in Renal Resistance Vessels With Aging and Hypertension , 2016, Kidney international reports.

[10]  J. O'Toole,et al.  APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease. , 2016, Journal of the American Society of Nephrology : JASN.

[11]  Dermot F. Reilly,et al.  Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort. , 2016, Journal of the American Society of Nephrology : JASN.

[12]  Catherine C. Robertson,et al.  Integrative Genomics Identifies Novel Associations with APOL1 Risk Genotypes in Black NEPTUNE Subjects. , 2016, Journal of the American Society of Nephrology : JASN.

[13]  M. Fornage,et al.  APOL1 Genotype and Race Differences in Incident Albuminuria and Renal Function Decline. , 2016, Journal of the American Society of Nephrology : JASN.

[14]  S. Alper,et al.  APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases , 2015, Proceedings of the National Academy of Sciences.

[15]  D. Vandorpe,et al.  BH3 domain-independent apolipoprotein L1 toxicity rescued by BCL2 prosurvival proteins. , 2015, American journal of physiology. Cell physiology.

[16]  C. Winkler,et al.  APOL1 Risk Alleles Are Associated with Exaggerated Age-Related Changes in Glomerular Number and Volume in African-American Adults: An Autopsy Study. , 2015, Journal of the American Society of Nephrology : JASN.

[17]  Patrick D. Dummer,et al.  APOL1 Kidney Disease Risk Variants: An Evolving Landscape. , 2015, Seminars in nephrology.

[18]  J. Hodgin,et al.  Podometrics as a Potential Clinical Tool for Glomerular Disease Management. , 2015, Seminars in nephrology.

[19]  A. Finkelstein,et al.  Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: Relevance to trypanosome lysis , 2015, Proceedings of the National Academy of Sciences.

[20]  B. Freedman,et al.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. , 2015, Journal of the American Society of Nephrology.

[21]  V. D’Agati,et al.  Innate immunity pathways regulate the nephropathy gene Apolipoprotein L1 , 2014, Kidney international.

[22]  R. Bosch,et al.  Plasma apolipoprotein L1 levels do not correlate with CKD. , 2014, Journal of the American Society of Nephrology : JASN.

[23]  John D Reveille,et al.  End‐Stage Renal Disease in African Americans With Lupus Nephritis Is Associated With APOL1 , 2014, Arthritis & rheumatology.

[24]  Barry I. Freedman,et al.  APOL1 risk variants, race, and progression of chronic kidney disease. , 2013, The New England journal of medicine.

[25]  M. Beggs,et al.  Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. , 2013, Journal of the American Society of Nephrology : JASN.

[26]  O. Kretz,et al.  Vps34 deficiency reveals the importance of endocytosis for podocyte homeostasis. , 2013, Journal of the American Society of Nephrology : JASN.

[27]  G. Genovese,et al.  APOL1 variants and kidney disease in people of recent African ancestry , 2013, Nature Reviews Nephrology.

[28]  S. Rosset,et al.  APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  P. Kimmel,et al.  Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  A. Ashley-Koch,et al.  MYH9 and APOL1 are both associated with sickle cell disease nephropathy , 2011, British Journal of Haematology.

[31]  N. Powe,et al.  Genetic variation in APOL1 associates with younger age at hemodialysis initiation. , 2011, Journal of the American Society of Nephrology : JASN.

[32]  J. O'Toole,et al.  APOL1 localization in normal kidney and nondiabetic kidney disease. , 2011, Journal of the American Society of Nephrology : JASN.

[33]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[34]  A. Zonderman,et al.  Poverty, race, and CKD in a racially and socioeconomically diverse urban population. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  M. Matsui,et al.  In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. , 2003, Molecular biology of the cell.

[36]  R. Brasseur,et al.  Apolipoprotein L-I is the trypanosome lytic factor of human serum , 2003, Nature.

[37]  C. Winkler,et al.  Therapeutics for APOL1 nephropathies: putting out the fire in the podocyte. , 2017, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  C. Macrae,et al.  From man to fish: What can Zebrafish tell us about ApoL1 nephropathy? , 2016, Clinical nephrology.

[39]  Barry I Freedman,et al.  Histopathologic findings associated with APOL1 risk variants in chronic kidney disease , 2015, Modern Pathology.